No Data
HK stocks anomaly | BeiGene Bio (06955) rose nearly 9%, initial signs of company scale effect. The number of similar bio-similar drugs on the market continues to accumulate and trade volume is increasing.
Bohai Biological (06955) increased by nearly 9%. As of the time of writing, it rose by 8.92%, priced at 8.3 Hong Kong dollars, with a transaction volume of 15.9053 million Hong Kong dollars.
[Focus on Brokerage] Zhongtai initiates coverage of Boan Biotech (06955) with a "shareholding" rating, indicating that the progress of listing products in relevant fields is leading among similar products.
Jingu Cai Xun | Zhongtai Securities issued research reports indicating that Boan Biologics (06955) continues to accumulate and expand its listing of biosimilar varieties. The revenue in 2021/2022/2023 reached 0.16, 0.52, 0.62 billion yuan respectively, and the revenue in the first half of 2024 reached 0.36 billion yuan. The company's economies of scale are beginning to show, with sales expense ratio, management expense ratio, and research and development expense ratio (R&D spending in 2024H1 decreased by approximately 40.2 million yuan. This is mainly due to the increase in R&D investment capitalization in the second half of 2023, with more R&D projects progressing to Phase III clinical trials and capitalization).
Additional Considerations Required While Assessing Shandong Boan Biotechnology's (HKG:6955) Strong Earnings
Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
BOAN BIOTECH: INTERIM REPORT 2024
Shandong Boan Biotechnology Swings to Profit in H1
Is Shandong Boan Biotechnology (HKG:6955) Using Too Much Debt?No Data
No Data
